Search | IOVS | ARVO Journals

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2023

Stability study of a preservative-free formulation of SYL1801, a siRNA indicated for neovascular AMD, in Novelia® multidose eye dropper

Veronica Ruz; Beatriz Vargas; Lola Company; Anne-Marie Bleau; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):736.

ARVO Annual Meeting Abstract June 2023

Long-term safety studies of tivanisiran for the treatment of Dry Eye Disease (DED)

Anne-Marie Bleau; Veronica Ruz; Beatriz Vargas; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3954.

ARVO Annual Meeting Abstract June 2022

Phase I of SYL1801, a new siRNA delivered in eye drops for age-related macular degeneration

Ana Isabel Jimenez; Veronica Ruz; Beatriz Vargas; Anne Marie Bleau

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):337 – F0168.

ARVO Annual Meeting Abstract June 2020

Tivanisiran as a new treatment for Dry Eye in patients with Sjögren Syndrome

Victoria Gonzalez; Veronica Ruz; Anne Marie Bleau; Beatriz Vargas; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):102.

ARVO Annual Meeting Abstract July 2019

Clinical Results of tivanisiran, a siRNA for the treatment of dry eye disease

Veronica Ruz; Victoria Gonzalez; Anne-Marie Bleau; Beatriz Vargas; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6738.

ARVO Annual Meeting Abstract July 2019

Safety & effect of tivanisiran eye drops on ocular surface: corneal sensitivity, mucin production and proinflammatory mediator’s expression

Victoria Gonzalez; Beatriz Vargas; Tamara Martinez; Amor Guerra; Veronica Ruz; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6746.

ARVO Annual Meeting Abstract July 2019

SYL1801: Preclinical Efficacy and Safety of a siRNA-based eye drops treatment for Age Related Macular Degeneration

Ana Isabel Jimenez; Veronica Ruz; Laura Rico; Tamara Martinez; Susana Monteiro; Ascension Cuesta; Amor Guerra; Alba Cuenca; Victoria Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5389.

ARVO Annual Meeting Abstract July 2018

Topical administration of siRNA targeting NRARP as a new treatment for choroidal neovascularization

Veronica Ruz; Covadonga Paneda; Tamara Martinez; Susana Monteiro; Amor Guerra; Victoria Gonzalez; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2634.

ARVO Annual Meeting Abstract July 2018

Development of a RNAi therapeutic for the treatment of allergic conjunctivitis

Victoria Gonzalez; Covadonga Paneda; Tamara Martinez; Amor Guerra; Susana Monteiro; Beatriz Vargas; Anne Marie Bleau; Veronica Ruz; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5567.

ARVO Annual Meeting Abstract July 2018

Tivanisiran, a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials

Ana Isabel Jimenez; Veronica Ruz; Victoria Gonzalez; Covadonga Paneda; Tamara Martinez; Beatriz Vargas; Anne Marie Bleau

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):925.

ARVO Annual Meeting Abstract June 2017

Efficacy of SYL1001 in different animal models of Dry Eye Disease

Ana Isabel Jimenez; Covadonga Pañeda; Tamara Martinez; Amor Guerra; Nuno Fonseca; Susana Monteiro; Cristian Salvador; Jesus Merayo-Lloves; Ignacio Alcalde; Veronica Ruz; Victoria Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):458.

ARVO Annual Meeting Abstract June 2017

Stability study of SYL1001 eye drops (a siRNA compound) for Dry Eye Disease in different containers

Veronica Ruz; Yolanda Ruiz; Carlos Astrain; Carlos Segura; Noelia Miguel; Carlos millan; Victoria Gonzalez; Maria D Company

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):476.

ARVO Annual Meeting Abstract June 2017

Clinical and preclinical study correlation for SYL1001, a new treatment for dry eye disease

Victoria Gonzalez; Veronica Ruz; Covadonga Pañeda; Anne-Marie Bleau; Beatriz Vargas; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2670.

Cornea November 2016

Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease

PDF

José Manuel Benitez-Del-Castillo; Javier Moreno-Montañés; Ignacio Jiménez-Alfaro; Francisco José Muñoz-Negrete; Krista Turman; Kadi Palumaa; Belén Sádaba; María Victoria González; Verónica Ruz; Beatriz Vargas; Covadonga Pañeda; Tamara Martínez; Anne-Marie Bleau; Ana Isabel Jimenez
TAGS: dry eye syndromes, placebos, rna, rna, small interfering, safety, phase 2 clinical trials, eye
Invest. Ophthalmol. Vis. Sci.. 2016; 57(14):6447-6454. https://doi.org/10.1167/iovs.16-20303

Includes: Supplemental Content

ARVO Annual Meeting Abstract September 2016

Results of clinical trials with a novel RNA-based therapy (SYL1001) to treat patients with ocular pain associated to dry eye disease

Ana Isabel Jimenez; Jose M Benitez Del Castillo; Javier Moreno-Montanes; Ignacio Jimenez-Alfaro; Francisco Muñoz-Negrete; Kadi Palumaa; Krista Turman; Covadonga Paneda; Tamara Martinez; Veronica Ruz; Victoria Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2878.

ARVO Annual Meeting Abstract September 2016

Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma

Victoria Gonzalez; Javier Moreno-Montanes; Maris Oll; Kenneth N Sall; Kadi Palumaa; Harvey Dubiner; Krista Turman; Francisco Muñoz-Negrete; Veronica Ruz; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3023.

ARVO Annual Meeting Abstract September 2016

Stability study of Bamosiran (a siRNA compound) in ophthalmic solution in different containers

Veronica Ruz; Victoria Gonzalez; Ana Isabel Jimenez; Lola Company; Yolanda Ruiz; Carlos Astrain

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3040.

ARVO Annual Meeting Abstract June 2015

Pharmacokinetic and Biosdistribution of Bamosiran in Human and Animal model, a Novel Treatment for Glaucoma

Victoria Gonzalez; Belen Sadaba; Javier Moreno-Montanes; Veronica Ruz; Covadonga Paneda; Ana Isabel Jimenez

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5748.

ARVO Annual Meeting Abstract April 2014

SYL1001, a new treatment based on RNAi for the treatment of ocular pain.

Veronica Ruz; Victoria Gonzalez; Carmen Martinez-Garcia; Covadonga Pañeda; Ana Isabel Jiménez

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3673.

ARVO Annual Meeting Abstract March 2012

SYL1001 for Treatment of Ocular Discomfort in Dry Eye: Safety and Tolerance (Phase I Study)

Victoria Gonzalez; Javier Moreno-Montañés; Belén Sádaba; Verónica Ruz; Ana Isabel Jímenez

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):575.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Stability study of a preservative-free formulation of SYL1801, a siRNA indicated for neovascular AMD, in Novelia® multidose eye dropper

Long-term safety studies of tivanisiran for the treatment of Dry Eye Disease (DED)

Phase I of SYL1801, a new siRNA delivered in eye drops for age-related macular degeneration

Tivanisiran as a new treatment for Dry Eye in patients with Sjögren Syndrome

Clinical Results of tivanisiran, a siRNA for the treatment of dry eye disease

Safety & effect of tivanisiran eye drops on ocular surface: corneal sensitivity, mucin production and proinflammatory mediator’s expression

SYL1801: Preclinical Efficacy and Safety of a siRNA-based eye drops treatment for Age Related Macular Degeneration

Topical administration of siRNA targeting NRARP as a new treatment for choroidal neovascularization

Development of a RNAi therapeutic for the treatment of allergic conjunctivitis

Tivanisiran, a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials

Efficacy of SYL1001 in different animal models of Dry Eye Disease

Stability study of SYL1001 eye drops (a siRNA compound) for Dry Eye Disease in different containers

Clinical and preclinical study correlation for SYL1001, a new treatment for dry eye disease

Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease

Results of clinical trials with a novel RNA-based therapy (SYL1001) to treat patients with ocular pain associated to dry eye disease

Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma

Stability study of Bamosiran (a siRNA compound) in ophthalmic solution in different containers

Pharmacokinetic and Biosdistribution of Bamosiran in Human and Animal model, a Novel Treatment for Glaucoma

SYL1001, a new treatment based on RNAi for the treatment of ocular pain.

SYL1001 for Treatment of Ocular Discomfort in Dry Eye: Safety and Tolerance (Phase I Study)

To View More...

You must be signed into an individual account to use this feature.